1. Search Result
Search Result
Results for "

TPPS

" in MCE Product Catalog:

18

Inhibitors & Agonists

2

Peptides

Cat. No. Product Name Target Research Areas
  • HY-W075353
    TPPS

    Others Cancer
    TPPS can be used as a non-cytotoxic probe for detecting tumor location.
  • HY-135868
    Mito-apocynin (C2)

    Mitochondrial Metabolism Neurological Disease
    Mito-apocynin (C2), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP + cation. Mito-apocynin (C2) exhibits antineuroinflammatory effect.
  • HY-151342
    [email protected]TPP@CUR

    Others Others
    [email protected]TPP@CUR is a Curcumin (HY-N0005) derivative. [email protected]TPP@CUR effectively ameliorates injured renal tubular epithelial cells and improves renal functions of acute kidney injury (AKI) mice. [email protected]TPP@CUR can be used for the research of AKI .
  • HY-P3139
    TPP-1

    PD-1/PD-L1 Cancer
    TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function.
  • HY-P3139A
    TPP-1 TFA

    PD-1/PD-L1 Cancer
    TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function.
  • HY-150070
    Butabindide

    UCL-1397

    Others Neurological Disease
    Butabindide (UCL-1397) is a potent, selective tripeptidvl peptidase II (TPP II) inhibitor with Ki values of 7 nM and 10 μM for TPP II and TPP I, respectively. Butabindide inhibits TPP II to protect CCK-8 against inactivation.
  • HY-107759
    Butabindide oxalate

    UCL-1397 oxalate

    Others Neurological Disease
    Butabindide (UCL-1397) oxalate is a potent, selective tripeptidvl peptidase II (TPP II) inhibitor with Ki values of 7 nM and 10 μM for TPP II and TPP I, respectively. Butabindide oxalate inhibits TPP II to protect CCK-8 against inactivation.
  • HY-144831
    6BrCaQ-C10-TPP

    HSP Cancer
    6BrCaQ-C10-TPP is a potent mitochondrial heat shock protein TRAP1 inhibitor, with antiproliferative activity in various human cancer cells (IC50=0.008-0.30 μM). 6BrCaQ-C10-TPP can also induces mitochondrial membrane disturbance.
  • HY-102007
    Gamitrinib TPP

    HSP Cancer
    Gamitrinib TPP is a Gamitrinib (GA) mitochondrial matrix inhibitor. Gamitrinib TPP is a mitochondrial targeted HSP90 inhibitor with anti-cancer activity.
  • HY-102007A
    Gamitrinib TPP hexafluorophosphate

    HSP Cancer
    Gamitrinib TPP hexafluorophosphate is a Gamitrinib (GA) mitochondrial matrix inhibitor. Gamitrinib TPP hexafluorophosphate is a mitochondrial targeted HSP90 inhibitor with anti-cancer activity.
  • HY-144768
    Chol-TPP

    Others Others
    Chol-TPP, a mitochondria targeting liposome ligand could be used in pH-redox responsive.
  • HY-100116A
    Mitoquinone mesylate

    MitoQ mesylate; MitoQ10 mesylate

    Reactive Oxygen Species Metabolic Disease Cancer
    Mitoquinone mesylate is a TPP-based, mitochondrially targeted antioxidant in order to protect against oxidative damage.
  • HY-135869
    Mito-apocynin (C11)

    Mitochondrial Metabolism Neurological Disease
    Mito-apocynin (C11), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP + cation. Mito-apocynin (C11) selectively targets mitochondria, and shows neuroprotective effect. Mito-apocynin (C11) prevents hyposmia and corrects deficits in motor function.
  • HY-103656
    Tetraphenylporphyrin

    TPP; Tetraphenylporphine; meso-Tetraphenylporphyrin

    Others Cancer
    Tetraphenylporphyrin (TPP) is a symmetrically substituted porphyrin-based heterocyclic compound and used as a structural block for supramolecular synthesis. Tetraphenylporphyrin derivatives can be used for cancer research.
  • HY-151404
    Antitumor agent-76

    Apoptosis Cancer
    Antitumor agent-76 (Compound TP-P1) is an orally active, rapid-release and water-soluble Triptolide (HY-32735) prodrug with antitumor activity.
  • HY-144830
    6BrCaQ

    HSP Cancer
    6BrCaQ is a potent mitochondrial heat shock protein TRAP1 inhibitor, with antiproliferative activity. 6BrCaQ can be used in the synthesis of 6BrCaQ-TPP conjugates.
  • HY-151556
    Antifungal agent 45

    Fungal Infection
    Antifungal agent 45 is with fungicidal activities. Antifungal agent 45 shows excellent characteristics superior to Kresoxim-methyl (HY-125776), in which the activity enhancement against Phytophthora capsici was the most remarkable, with an EC50 value of about 5 μM.
  • HY-144825
    Chol-CTPP

    Apoptosis Reactive Oxygen Species Cancer
    Chol-CTPP is a ligand with dual targeting effect on blood-brain barrier (BBB) and glioma cells. Lip-CTPP can be gained by Chol-CTPP and another mitochondria targeting ligand (Chol-TPP). Lip-CTPP is a promising potential carrier to exert the anti-glioma effect of doxorubicin (DOX) and lonidamine (LND) collaboratively. Lip-CTPP elevates the inhibition rate of tumor cell proliferation, migration and invasion, promote apoptosis and necrosis, and interfere with mitochondrial function.